Objective-In addition to an extensively characterized role of high-density lipoprotein (HDL) in reverse cholesterol transport, bioactive lipids bound to HDL can also exert diverse vascular effects. Despite this, integration of HDL action in the vasculature with pathways that metabolize HDL and release bioactive lipids has been much less explored. The effects of HDL on endothelial cells are mediated in part by HDL-associated sphingosine 1-phosphate (S1P), which binds to S1P 1 receptors and promotes activation of endothelial NO synthase (eNOS) and the kinase Akt. In these studies, we characterized the role of endothelial lipase (EL) in the control of endothelial signaling and biology, including those mediated by HDL-associated S1P. Approach and Results-HDL-induced angiogenesis in aortic rings from EL-deficient (EL −/− ) mice was markedly decreased compared with wild-type controls. In cultured endothelial cells, small interfering RNA-mediated knockdown of EL abrogated HDL-promoted endothelial cell migration and tube formation. Small interfering RNA-mediated EL knockdown also attenuated HDL-induced phosphorylation of eNOS 1179 and Akt 473 . S1P stimulation restored HDL-induced endothelial migration and Akt/eNOS phosphorylation that had been blocked by small interfering RNA-mediated EL knockdown. HDL-induced endothelial cell migration and Akt/eNOS phosphorylation were completely inhibited by the S1P 1 antagonist W146 but not by the S1P 3 antagonist CAY10444. Conclusions-EL is a critical determinant of the effects of HDL on S1P-mediated vascular responses and acts on HDL to promote activation of S1P 1 , leading to Akt/eNOS phosphorylation and subsequent endothelial migration and angiogenesis. The role of EL in HDL-associated S1P effects provides new insights into EL action, the responses seen through EL and HDL interaction, and S1P signaling. (Arterioscler Thromb Vasc Biol. 2013;33:1788-1794.)
P lasma levels of high-density lipoprotein cholesterol (HDL-C) are inversely associated with the risk of cardiovascular diseases. 1 The antiatherogenic effect of HDL is attributed at least in part to reverse cholesterol transport. 2 In addition, multiple lines of evidence indicate that other salutary effects of HDL on endothelial cells (ECs) include antioxidative, anti-inflammatory, antithrombotic, and proangiogenic effects. [3] [4] [5] HDL is the most quantitatively important plasma carrier of sphingosine-1-phosphate (S1P), which is a bioactive lipid molecule. HDL-associated S1P has been demonstrated to be involved in a broad range of vascular responses [6] [7] [8] [9] modulated by a family of ≥5 different S1P receptor subtypes identified in mammals; ECs express most prominently the S1P 1 and S1P 3 receptor isoforms. 9, 10 It was recently reported that HDL-induced Akt activation and endothelial responses are mediated by S1P 1 in human umbilical vein ECs. 11 In contrast, other studies suggest that HDL-induced Akt activation is mediated by S1P 3 receptors. 12 The identity of the S1P receptor subtype that modulates HDL responses in the endothelium remains unsettled, and the mechanisms whereby S1P is released from HDL is unclear. The studies presented here explore the roles of endothelial lipase (EL) and the identity of the S1P receptor subtype in determining HDL-dependent responses in the vascular wall.
EL is a member of the triglyceride lipase family, which includes lipoprotein lipase and hepatic lipase. EL is principally a phospholipase, with nominal triglyceride lipase activity. 13, 14 EL is synthesized principally by ECs 15 and hydrolyzes HDL much more efficiently than other lipoproteins. 16 Plasma HDL levels are increased in EL knockout (EL −/− ) mice and are decreased in EL transgenic mice. 17 Furthermore, the N396S variant in the human EL gene (LIPG) shows reduced lipase activity and is associated with elevated HDL-C levels. 18 Another EL variant, G26S EL shows reduced plasma levels of EL protein. 19 Yet the role of EL in atherosclerosis remains controversial. Inactivation of EL increases the plasma HDL-C levels and inhibits atherosclerosis in ApoE −/− mice. 20 In contrast, another study reported that a deficiency of EL expression does not affect atherosclerosis in either ApoE −/− mice or LDLR −/− mice, although plasma HDL-C levels are elevated. 21 Broedl et al 22 have shown that EL overexpression results in reduced very-low-density lipoprotein/ low-density lipoprotein cholesterol and phospholipid levels. In addition, we have previously reported that HDL hydrolysis by EL activates peroxisome proliferator activated receptorα and represses vascular cell adhesion molecule 1 expression in ECs, which may contribute to the anti-inflammatory effects of HDL. 23 These multiple lines of evidence suggest EL action might limit atherosclerosis. Several genetic association studies have shown conflicting results about the association between common genetic variants in LIPG gene and the risk of cardiovascular diseases. Vergeer et al 24 reported that the T111I variant in the LIPG gene is associated with higher HDL-C levels but is not related to cardiovascular disease risk. Moreover, recent Mendelian randomization analysis studies in 20 913 myocardial infarction cases compared with 95 407 controls found that a single nucleotide polymorphism in the EL gene significantly increased HDL-C levels but conferred no protection against myocardial infarction. 25 These findings raise questions about the connection between plasma HDL-C levels, per se, and protection against atherosclerosis and the connection between the enzymatic function of EL and the vascular effects of HDL. Sphingosine 1-phosphate (S1P) is a bioactive lipid that binds to a family of G protein-coupled receptors that modulate signaling responses in multiple cells and tissues. 26 S1P 1 receptors in the vascular endothelium are reversibly targeted to plasmalemmal caveolae and promote the activation of kinase Akt and of the endothelial isoform of NO synthase (eNOS), leading to vasorelaxation. 27 The EC 50 for S1Ppromoted eNOS phosphorylation is ≥1 order of magnitude lower than the plasma concentration of S1P, reflecting the fact that plasma S1P is mostly bound to plasma proteins. HDL particles represent the predominant S1P-carrier in plasma, with recent studies revealing apolipoprotein M in HDL as a specific S1P-binding protein. 28, 29 The roles of EL in modulating HDL-dependent signaling responses via S1P have not been well characterized. The current studies use experiments in ex vivo vascular preparations as well as in cultured ECs to test the hypothesis that HDL hydrolysis by EL induces angiogenesis and stimulates endothelial signaling responses via S1P 1 receptors in the vascular endothelium.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

EL Is Involved in HDL-Induced Endothelial Proliferation, Tube Formation, and Angiogenesis
Given EL as the predominant lipase expressed by ECs, we first studied the effects of the general lipase inhibitor tetrahydrolipstatin on HDL-induced EC migration. Addition of HDL (100 μg/mL) approximately doubled EC migration as compared with vehicle stimulation, an effect blocked by tetrahydrolipstatin-mediated lipase inhibition ( Figure 1A and 1B). To more directly investigate the role of EL in HDL-induced cell migration, bovine aortic ECs were transfected with a duplex small interfering RNA (siRNA) construct targeting EL. Bovine aortic ECs transfection with EL siRNA reduced EL mRNA by 90% and EL protein abundance by 50% reduction ( Figure IA in the online-only Data Supplement), but had no effect on eNOS, Akt, AMP-activated protein kinase, ERK1/2, p38MAPK, or PTEN protein levels ( Figure IB in the onlineonly Data Supplement). siRNA-mediated EL knockdown suppressed HDL-promoted EC migration ( Figure 1C and 1D); control siRNA had no effect on the HDL-induced migration response. Viability assays revealed that HDL increased EC viability but not after siRNA-mediated EL knockdown ( Figure 1E ). Similarly, HDL stimulation increased EC proliferation ( Figure 1F ) but not after EL siRNA exposure.
HDL stimulation of ECs promoted endothelial tube formation, which was also inhibited by siRNA-mediated EL knockdown, as seen on microscopy ( Figure 2A ) and after quantification of the average total tube length per field of view ( Figure 2B ).
Next, we used ex vivo angiogenesis in aortic rings model to evaluate the role of EL in HDL-induced angiogenesis. HDL markedly stimulated angiogenesis in aortic rings isolated from wild-type (WT) mice but not EL −/− knockout mice ( Figure 3A ), as quantified using the total area of new vessel formation ( Figure 3B ).
siRNA-Mediated EL Knockdown Inhibits HDL-Induced Phosphorylation Responses
To elucidate the signaling pathways responsible for these HDLmediated EL-dependent migration and angiogenesis responses, we examined the phosphorylation pattern of several key endothelial signaling proteins in response to HDL in the presence or absence of EL RNA interference. As shown in Figure 4 , HDL treatment promoted the time-and dose-dependent phosphorylation of eNOS Ser 1179 and of kinase Akt, yielding a 2.0-fold (n=3; P<0.01) increase in eNOS phosphorylation and a 3.7-fold (n=3; P<0.01) increase in Akt phosphorylation. siRNA-mediated EL knockdown attenuated HDL-induced eNOS and Akt phosphorylation, as assessed both in dose-response ( Figure 4A 
HDL-Stimulated EL-Dependent Signaling
Responses Are Mediated by S1P/S1P 1 S1P signals through distinct S1P receptor subtypes. We used S1P receptor subtype-selective antagonists to assess the role of HDL-bound S1P in HDL-induced EC migration ( Figure 5 ) and Akt/eNOS phosphorylation ( Figure 6A ) responses mediated by EL. The S1P 1 antagonist W146 blocked HDL-induced EC migration and Akt/eNOS phosphorylation. In contrast, the S1P 3 antagonist CAY10444 did not alter either HDL-induced EC migration or Akt/eNOS phosphorylation. Direct stimulation of cells with S1P itself reversed the inhibition seen with EL siRNA on both HDL-induced EC migration ( Figure 5 ) and Akt/eNOS phosphorylation ( Figure 6 ). Given these findings that EL can modulate HDL-induced endothelial responses via S1P, we sought to investigate differences in S1P levels in plasma from WT and EL-deficient mice. After developing and validating a liquid chromatography, tandem mass spectroscopy method in our laboratory for detecting S1P levels in murine plasma, we documented S1P concentrations in murine plasma in the high nanomolar range ( Figure II in the online-only Data Supplement). S1P plasma levels did not differ between WT (n=4) and EL-deficient male mice (n=6; Figure 6B ).
Discussion
We have used siRNA and pharmacological approaches in cultured ECs, as well as analyses using knockout mouse models, to study the roles of EL and S1P in HDL-induced angiogenesis and signaling responses. We found that EL loss-offunction, through either the lipase inhibitor tetrahydrolipstatin or through siRNA-mediated EL knockdown, markedly attenuated HDL-induced EC migration ( Figure 1A-1D ), proliferation ( Figure 1E and 1F), and tube formation ( Figure 2 ). HDL-induced angiogenesis was also inhibited in ex vivo studies of aortic rings from EL-deficient mice (Figure 3 ). HDLpromoted Akt and eNOS phosphorylation was markedly inhibited after siRNA-mediated EL knockdown ( Figure 4 ). The effects of EL/HDL on EC migration ( Figure 5 ) as well as Akt and eNOS phosphorylation ( Figure 6 ) were blocked by an antagonist to S1P 1 but not S1P 3 , whereas S1P stimulation reversed the inhibition of these endothelial responses seen with EL siRNA exposure. Taken together, these experiments, using lipase inhibitors, siRNA approaches, and a genetic mouse model, strongly implicate EL as a key determinant of HDL-mediated physiological responses in the endothelium.
HDL elicits a broad range of physiological and signaling responses in the endothelium. 30, 31 Importantly, HDL may induce substantively different responses in distinct vascular beds and experimental models. For example, HDL promotes tube formation through Ras/ERK1/2 signaling pathway in human coronary artery ECs, 3 whereas Akt-dependent pathways seem to modulate HDL responses in human umbilical vein ECs. 32 Other studies implicate AMP-activated protein kinase in HDL responses, including eNOS phosphorylation. 33 The role of EL in mediating these and other HDL effects has not been well explored. Our findings suggest that differential expression and activity of EL may be an under-recognized variable influencing HDL responses seen in various experimental models and perhaps in vivo as well.
The roles of EL-mediated HDL hydrolysis in atherosclerosis remain incompletely understood, with unresolved controversies in the field. Hara et al 34 reported that HDL from EL knockout mice retained the anti-inflammatory features seen in HDL isolated from WT mice. Moreover, Riederer et al 35 reported that lysophosphatidylcholine generated by the action of EL on HDL induced the expression of interleukin-8, a proinflammatory and proadhesive chemokine. 24 These results lend support to the view that hydrolysis of HDL by EL has proinflammatory properties. In contrast, we previously reported that EL overexpression decreased tumor necrosis factor-α-induced vascular cell adhesion molecule 1 expression and promoter activity through peroxisome proliferator activated receptor-α activation in ECs, thus limiting vascular inflammation. 23 Interestingly, individuals with EL-loss-offunction variants have higher HDL but no apparent protection against atherosclerosis or its complications. 25 In the present study, we have shown that HDL exposure to EL induces angiogenesis and promotes Akt/eNOS activation. Angiogenic therapies have been explored for treating cardiovascular diseases, yet clearly a complex, dynamic balance of pro-and antiangiogenic pathways exist and may vary in different physiological and pathological settings. 36 Our data suggest HDL and changes in EL expression and function as potential contributors to these patterns. Further elucidation about mechanisms through which HDL and HDL interaction with EL exert biological effects may provide insight into divergent data sets about the impact of HDL, HDL-modulating therapy, and genetic EL variants on atherosclerosis.
The data provided here implicate S1P as a possible mediator of responses induced by HDL through EL action. The S1P 1 receptor antagonist W146 blocked HDL-induced EC migration as well as Akt/eNOS phosphorylation, whereas the S1P 3 antagonist CAY10444 did not affect either HDL-induced EC migration or Akt/eNOS phosphorylation. Decreased EL levels, as achieved with siRNA, inhibited HDL-induced EC migration and Akt/eNOS phosphorylation, responses that were restored by adding back S1P (Figures 5 and 6 ). Our results support the hypothesis of S1P as a key HDL constituent generated by EL that can induce angiogenesis and elicit Akt/eNOS signaling responses. S1P and its receptors have been implicated in HDLstimulated Akt/eNOS phosphorylation. 11, 32, 35 We previously reported that free S1P activates eNOS through phosphoinositol 3-kinase/Akt signaling pathways, 27, 37 a finding consistent with the current studies showing that HDL-associated S1P elicits similar effects. It is quite likely that other bioactive lipids in addition to S1P are liberated after hydrolysis of HDL by EL. Indeed, the precise mechanism(s) through which EL promotes HDL-dependent S1P release and signaling remains to be determined. EL reportedly catalyzes the conversion of large HDL2 particles to small HDL3 particles, which are more highly enriched in S1P relative to large HDL2 particles. [38] [39] [40] In addition, EL may also augment S1P effects by reducing S1P catabolism, inhibiting S1P lyase, or facilitating S1P delivery.
Based on our findings, it will be of particular interest to consider how apolipoprotein M, as a recently identified S1P-binding partner in HDL, 28, 29 might be involved in the EL-mediated effects reported here. One recent studied analyzed S1P plasma levels in relationship to apolipoprotein M in different monogenic disorders of HDL metabolism. 41 In that work, considerable variability in S1P levels was seen among the 10 Dutch patients with LIPG (EL) gene variations, which the authors speculated could have resulted from various issues. Our inability to detect changes in S1P levels in WT compared with EL-deficient mouse plasma may have been influenced by multiple factors. Total plasma S1P reflects heterogenous protein-bound S1P pools. The levels of S1P actually bound to isolated murine HDL might be a more relevant measure, but has not been routinely performed in the field and remains technically challenging (data not shown). The total plasma S1P concentration in mice does far exceed the EC50 for S1P-promoted Akt phosphorylation or eNOS activation (2-10 nmol/L), 37 arguing for the biological plausibility of this mechanism. The possibility that EL might be involved in S1P release from HDL, either directly or indirectly, has been raised in various models 38 but, to our knowledge, the results presented here are the first that directly support this prospect. Of note, ABCA1, ABCG1, and SR-B1, important transporter proteins in HDL pathways, have all been implicated in S1P handling. 39 We also provide evidence that S1P released from HDL by EL activates S1P 1 receptors that promote Akt/eNOS activation. Although other model systems have implicated both S1P 3 and S1P 1 receptors in these responses, 39, 40 we found an S1P 3 antagonist did not inhibit HDL-dependent effects in our system, whereas an S1P 1 antagonist completely blocked responses to HDL. Bovine aortic ECs do express both S1P 3 and S1P 1 . 42, 43 Our experiments using S1P receptor subtypeselective antagonists identify the S1P 1 receptor subtype as the principal receptor mediating the HDL response in these ECs.
Taken together, these findings reveal EL as a key player in facilitating the activation of HDL-dependent signals that lead to S1P 1 receptor activation as well as Akt and eNOS phosphorylation, with functional effects on EC migration, tube formation, and angiogenesis (Figure 7) . These results provide new insights into the molecular mechanisms through which HDL, EL, and their interaction may modulate angiogenesis and vascular responses. Figure 6 . Sphingosine 1-phosphate (S1P)/S1P 1 is involved in high-density lipoprotein (HDL)-induced phosphorylation of endothelial NO synthase (eNOS) and Akt mediated by endothelial lipase. A, Immunoblots were analyzed in bovine aortic endothelial cells transfected with control or endothelial lipase (EL) small interfering RNA (siRNA) after treatment with vehicle, HDL (75 μg/mL), HDL (75 μg/mL) + W146 (10 μmol/L), HDL (75 μg/mL) + CAY10444 (10 μmol/L), or S1P (100 nmol/L). Vehicle or W146 was added to the cells 1 hour before addition of HDL or S1P. Cell lysates were harvested 5 minutes after adding HDL or S1P and analyzed in immunoblots probed with specific antibodies against Ser 1179 -phospho-eNOS (peNOS 1179 ), Ser 473 -phospho-Akt (pAkt 473 ), and total eNOS and Akt. The experiment shown is a representative of 3 independent experiments. *P<0.05, **P<0.01 vs control siRNA with the same treatment, † †P<0.01 vs control siRNA with vehicle. Data represent mean±SEM. B, S1P plasma levels from wild-type (WT; n=4) and EL-deficient mice (n=6) do not differ on LC/MS/MS measurement (also see Figure II in the online-only Data Supplement).
Figure 7.
Model of endothelial lipase (EL)-mediated high-density lipoprotein (HDL)-dependent signaling via S1P/S1P 1 pathways. The data presented here suggest that HDL hydrolysis by endothelial lipase can release biologically active molecules that promote Akt and endothelial NO synthase (eNOS) phosphorylation in endothelial cells, with functional effects promoting endothelial cell migration, tube formation, and angiogenesis. These EL/HDL responses seem to involve HDL-bound S1P, which then binds to S1P 1 receptors, inducing these endothelial effects. Key proteins involved in HDL biology, including SR-B1, ABC1, and ABCG8, have all been implicated in S1P transport. ABCA1 and ABCG1 indicate ATPbinding cassette transporters; ApoA-I. apolipoprotein A-I; HSPG, heparan sulfate proteoglycan; and SR-BI scavenger receptor class B type I.
Controversies persist about the relationship between high-density lipoprotein (HDL) and atherosclerosis. Despite a well-validated inverse relationship between HDL levels and cardiovascular events in epidemiological studies, HDL-raising therapies levels have not shown clear clinical benefit in prospective, randomized clinical trials. Moreover, recent data reveal that genetic loss-of-function endothelial lipase (EL) variants have increased HDL levels without any obvious protection against cardiovascular events. Extensive studies now establish that specific lipases can exert many distinct and important biological effects. We provide evidence here that EL interacts with HDL to promote angiogenesis, increase endothelial proliferation, and endothelial cell signaling via endothelial NO synthase and aKT phosphorylation. These EL/HDL seem to involve the release of sphingosine-1 phosphate and signaling through the S1P 1 receptor. These data provide new perspectives on how EL interaction with HDL may modulate endothelial responses through S1P release and offer an example of how EL deficiency might result in a loss of potentially beneficial effects.
Significance
